MediciNova, Inc. (NASDAQ:MNOV) – Equities research analysts at Zacks Investment Research issued their Q1 2018 earnings estimates for MediciNova in a research report issued on Friday. Zacks Investment Research analyst D. Bautz anticipates that the biopharmaceutical company will post earnings per share of ($0.12) for the quarter. Zacks Investment Research also issued estimates for MediciNova’s Q2 2018 earnings at ($0.11) EPS, Q3 2018 earnings at ($0.11) EPS, Q4 2018 earnings at ($0.11) EPS and FY2020 earnings at ($0.41) EPS.
Several other research analysts also recently weighed in on the stock. BidaskClub raised shares of MediciNova from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 7th. ValuEngine raised shares of MediciNova from a “sell” rating to a “hold” rating in a research note on Wednesday, February 7th.
Hedge funds have recently made changes to their positions in the stock. Voya Investment Management LLC raised its stake in MediciNova by 22.9% in the 2nd quarter. Voya Investment Management LLC now owns 19,341 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 3,603 shares during the last quarter. Jane Street Group LLC acquired a new position in MediciNova in the 3rd quarter valued at about $118,000. The Manufacturers Life Insurance Company raised its stake in MediciNova by 1,645.0% in the 4th quarter. The Manufacturers Life Insurance Company now owns 29,002 shares of the biopharmaceutical company’s stock valued at $187,000 after purchasing an additional 27,340 shares during the last quarter. Paloma Partners Management Co acquired a new position in shares of MediciNova during the 4th quarter valued at about $198,000. Finally, Wells Fargo & Company MN increased its stake in shares of MediciNova by 63.3% during the 3rd quarter. Wells Fargo & Company MN now owns 32,575 shares of the biopharmaceutical company’s stock valued at $208,000 after acquiring an additional 12,624 shares during the last quarter. 18.52% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.com-unik.info/2018/02/21/zacks-investment-research-weighs-in-on-medicinova-inc-s-q1-2018-earnings-mnov.html.
Medicinova, Inc is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin).
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.